What we do Metropolis Healthcare Ltd is a leading diagnostic company in India providing a wide range of pathology and specialized clinical laboratory services via extensive lab and service networks. |
Founded in 1,980 |
Market share Strong leadership in West and South India with presence in 600 towns, expanding rapidly in North and East India. |
Problem solved Provides accurate, early disease detection and monitoring services to improve patient outcomes and support clinical and research needs. |
Top clients or who we serve Serves patients via B2C centers and hospitals, corporate clients, government centers, and clinical research organizations (B2B and B2G). |
Key management Ameera Shah (Chairperson & Whole-time Director), Surendran Chemmenkotil (Managing Director), Sameer Patel (Chief Financial Officer). |
Our journey and innovations Started in 1980, evolved through partnerships and amalgamations, IPO in 2019; introduced AI-powered diagnostics, Next Generation Sequencing, and extensive digital transformation. |
Where we operate Operates across 219 cities in India and in Ghana, Kenya, Zambia, Mauritius, and Sri Lanka with partner presence in Nepal, Nigeria, UAE, and Oman. |
Top products or what we offer Offers ~4,000 clinical tests including routine, specialty, wellness, genomics (NGS), and AI-powered diagnostic tests. |
Top brands Metropolis Diagnostic Network, TruHealth Wellness Packs, Core Diagnostics (oncology/genomics), Metrodocs Clinician Membership. |
Raw materials needed - |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily recurring from diagnostic test services, wellness packages, and clinical research support. |
Our industry position Among the top diagnostic chains in India with ~11% CAGR revenue growth over 7 years, expanding market presence and specialty offerings. |
Financial highlights FY25 consolidated revenue Rs 1331 Cr, PAT Rs 145 Cr; 15% organic revenue growth YoY; EBITDA margin expanded over 25%. |
Geographical revenue split India accounts for ~92% revenue, rest from international operations in Africa and Asia-Pacific. |
Order book - |
Whats driving growth Digital transformation, specialty testing (genomics, NGS), expansion into tier II/III cities, wellness services, and acquisitions. |
Our future plans Expand lab and franchise network aggressively, deepen specialty and genomics portfolio, invest in AI diagnostics and adjacent healthcare services. |
Our green promise Committed to carbon neutrality by 2043, energy efficiency, waste reduction, and sustainable water management initiatives. |
Our people and values Employs diverse teams focused on innovation, quality, compliance, and patient-centric service delivery. |
Key challenges ahead Scaling operations across diverse geographies while maintaining quality, handling regulatory compliance, and integrating acquisitions. |
Interesting facts First listed diagnostic company with patented AI-based TB diagnostic system and leader in AI-enabled cancer diagnostics. |
Risks and strategy Mitigates risks through strong governance, quality controls, technology upgrades, and diversified service offerings. |
